Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Gemcitabine and Cisplatin in Advanced Biliary Tract Carcinomas
NCT00919061Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2009
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in biliary tract carcinoma (BTC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Progression-Free Survival at 6 months and Median Progression-Free Survival at 6 months. Started Aug 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT00919061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00919061.